Mantle Cell Lymphoma Clinical Trials

453 clinical trials for Mantle Cell Lymphoma across international registries, including 99 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies — RECRUITING · PHASE1
• Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy — RECRUITING · PHASE2
• A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. — RECRUITING · PHASE1
• Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies — RECRUITING · PHASE1
• Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax — RECRUITING
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — RECRUITING · PHASE1
• Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma — RECRUITING · PHASE3
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies — RECRUITING · PHASE1
• A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain — RECRUITING · PHASE2
• A Long-term Extension Study of PCI-32765 (Ibrutinib) — RECRUITING · PHASE3
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies — RECRUITING · PHASE1
• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas — RECRUITING · PHASE2
• IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas — RECRUITING · PHASE1
• Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease — RECRUITING · PHASE2
• This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma — RECRUITING · PHASE2
• Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) — RECRUITING · PHASE2
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) — RECRUITING · PHASE3
• Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma — RECRUITING · PHASE1
• Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms — RECRUITING
• DALY II USA/ MB-CART2019.1 for DLBCL — RECRUITING · PHASE2
• Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients — RECRUITING · PHASE1
• Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma — RECRUITING
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy — RECRUITING · PHASE2
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients (PLATO) — RECRUITING · PHASE2
• Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma — RECRUITING · PHASE2
• CD70-targeted immunoPET Imaging of Malignant Cancers — RECRUITING · PHASE2
• Prospective Examination on Neurocognitive Outcomes Following Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy — RECRUITING
• Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients — RECRUITING · PHASE2
• A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma — RECRUITING · PHASE2
• Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients — RECRUITING · PHASE2
• Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma — RECRUITING · PHASE2
• Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma — RECRUITING · PHASE1
• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader — RECRUITING · PHASE1
• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma — RECRUITING · PHASE1
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies — RECRUITING · PHASE1
• Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL — RECRUITING · PHASE2
• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma — RECRUITING · PHASE2
• Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study — RECRUITING
• CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies — RECRUITING · PHASE1

Refine this search